Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
He has over 23 years of experience across sectors
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Plans underway to expand screening capacity by 50% for greater accessibility
Branded formulation business continues to perform well across domestic and export markets
Subscribe To Our Newsletter & Stay Updated
